Connect with us

Published

on

Kate Ryder, CEO of Maven, speaking at the CNBC Changemakers Summit in New York on April 18th, 2024.

Danielle DeVries | CNBC

Maven Clinic, a health-care startup for women and families, announced Tuesday that it has closed a $125 million funding round at a $1.7 billion valuation. 

The company seeks to offer patients virtual care across their entire reproductive life cycle, whether they are planning a family, pregnant, postpartum or into menopause. Maven has raised a total of more than $425 million, and it will use its fresh capital to invest in its fertility benefits, expand its platform and leverage real-time data to deliver more proactive care to members. 

Maven CEO Kate Ryder told CNBC she founded the company in 2014 after watching her friends struggle to find the support they needed while building their families. Ten years later, Maven covers about 17 million lives through its contracts with health plans and employers, including companies like Amazon, Microsoft and AT&T

“Digital health is just at the very beginning,” Ryder told CNBC. 

The company was the first U.S. startup dedicated to women’s and family health to ever reach “unicorn” status, or a valuation of more than $1 billion. Some of Maven’s investors include firms like General Catalyst, Sequoia and Oak HC/FT, as well as celebrities like Oprah Winfrey, Mindy Kaling and Reese Witherspoon. 

Ryder said Maven is focusing on its product road map for now but that it aims to go public eventually. The company has secured a spot on the CNBC Disruptor 50 list for the last three years in a row. 

Couple using Maven Clinic

Courtesy of Maven

Women’s health, especially women’s reproductive health, is a hot-button issue in the upcoming election between Vice President Kamala Harris and former President Donald Trump. Ryder said Maven is open to sharing data and its perspective on policy regardless of which administration wins. 

After the U.S. Supreme Court overturned Roe v. Wade in June of 2022, Maven found itself in the spotlight as it worked to help employers navigate the emerging gaps in care. Ryder called the ruling a “devastating step back for healthcare in the United States” in a blog post at the time, adding that its clients could use Maven to reimburse patients’ travel across state lines.

The company saw a 67% month-over-month increase in interest in travel benefits and health care for pregnant people after the ruling. 

That same year, venture investments in women’s health companies ticked up 5%, according to a February report from Deloitte. Maven closed a $90 million funding round that November. Venture funding for the overall health tech market fell 27% during the same period, the report said.  

The amount of data available about women’s health is also improving, in part thanks to companies like Maven. In a post-Roe world, however, Ryder notes the information is often bleak, especially as experts are “starting to see a fuller picture of preventable death because of restricted access to care.” 

“I think between more funding and research, more data points from states, from platforms like ourselves, you can start to point and paint a complete picture of everything going on that helps change policy for the better,” Ryder said. “The question is, to be honest, when? And how many more people need to needlessly suffer in the meantime?”

Don’t miss these insights from CNBC PRO

Continue Reading

Technology

Waymo to begin testing in Philadelphia with safety drivers behind the wheel

Published

on

By

Waymo to begin testing in Philadelphia with safety drivers behind the wheel

A Waymo autonomous self-driving Jaguar electric vehicle sits parked at an EVgo charging station in Los Angeles, California, on May 15, 2024.

Patrick T. Fallon | AFP | Getty Images

Waymo said it will begin testing in Philadelphia, with a limited fleet of vehicles and human safety drivers behind the wheel.

“This city is a National Treasure,” Waymo wrote in a post on X on Monday. “It’s a city of love, where eagles fly with a gritty spirit and cheese that spreads and cheese that steaks. Our road trip continues to Philly next.”

The Alphabet-owned company confirmed to CNBC that it will be testing in Pennsylvania’s largest city through the fall, adding that the initial fleet of cars will be manually driven through the more complex parts of Philadelphia, including downtown and on freeways.

“Folks will see our vehicles driving at all hours throughout various neighborhoods, from North Central to Eastwick, and from University City to as far east as the Delaware River,” a Waymo spokesperson said.

With its so-called road trips, Waymo seeks to collect mapping data and evaluate how its autonomous technology, Waymo Driver, performs in new environments, handling traffic patterns and local infrastructure. Road trips are often used a way for the company to gauge whether it can potentially offer a paid ride share service in a particular location.

The expanded testing, which will go through the fall, comes as Waymo aims for a broader rollout. Last month, the company announced plans to drive vehicles manually in New York for testing, marking the first step toward potentially cracking the largest U.S. city. Waymo applied for a permit with the New York City Department of Transportation to operate autonomously with a trained specialist behind the wheel in Manhattan. State law currently doesn’t allow for such driverless operations.

Waymo One provides more than 250,000 paid trips each week across Phoenix, San Francisco, Los Angeles, and Austin, Texas, and is preparing to bring fully autonomous rides to Atlanta, Miami, and Washington, D.C., in 2026.

Alphabet has been under pressure to monetize artificial intelligence products as it bolsters spending on infrastructure. Alphabet’s “Other Bets” segment, which includes Waymo, brought in revenue of $1.65 billion in 2024, up from $1.53 billion in 2023. However, the segment lost $4.44 billion last year, compared to a loss of $4.09 billion the previous year.

WATCH: We went to Texas for Tesla’s robotaxi launch

We went to Texas for Tesla's robotaxi launch. Here's what we saw

Continue Reading

Technology

Trump advisor Navarro rips Apple’s Tim Cook for not moving production out of China fast enough

Published

on

By

Trump advisor Navarro rips Apple's Tim Cook for not moving production out of China fast enough

Peter Navarro: 'Inconceivable' that Apple could not produce iPhones outside China

White House trade advisor Peter Navarro chastised Apple CEO Tim Cook on Monday over the company’s response to pressure from the Trump administration to make more of its products outside of China.

“Going back to the first Trump term, Tim Cook has continually asked for more time in order to move his factories out of China,” Navarro said in an interview on CNBC’s “Squawk on the Street.” “I mean it’s the longest-running soap opera in Silicon Valley.”

CNBC has reached out to Apple for comment on Navarro’s criticism.

President Donald Trump has in recent months ramped up demands for Apple to move production of its iconic iPhone to the U.S. from overseas. Apple’s flagship phone is produced primarily in China, but the company has increasingly boosted production in India, partly to avoid the higher cost of Trump’s tariffs.

Trump in May warned Apple would have to pay a tariff of 25% or more for iPhones made outside the U.S. In separate remarks, Trump said he told Cook, “I don’t want you building in India.”

Read more CNBC tech news

Analysts and supply chain experts have argued it would be impossible for Apple to completely move iPhone production to the U.S. By some estimates, a U.S.-made iPhone could cost as much as $3,500.

Navarro said Cook isn’t shifting production out of China quickly enough.

“With all these new advanced manufacturing techniques and the way things are moving with AI and things like that, it’s inconceivable to me that Tim Cook could not produce his iPhones elsewhere around the world and in this country,” Navarro said.

Apple currently makes very few products in the U.S. During Trump’s first term, Apple extended its commitment to assemble the $3,000 Mac Pro in Texas.

In February, Apple said it would spend $500 billion within the U.S., including on assembling some AI servers.

WATCH: Apple’s $500 billion investment: For AI servers not manufacturing iPhones

Apple's $500 billion U.S. investment: For AI servers not manufacturing iPhones

Continue Reading

Technology

CoreWeave to acquire Core Scientific in $9 billion all-stock deal

Published

on

By

CoreWeave to acquire Core Scientific in  billion all-stock deal

CoreWeave founders Brian Venturo, at left in sweatshirt, and Mike Intrator slap five after ringing the opening bell at Nasdaq headquarters in New York on March 28, 2025.

Michael M. Santiago | Getty Images News | Getty Images

Artificial intelligence hyperscaler CoreWeave said Monday it will acquire Core Scientific, a leading data center infrastructure provider, in an all-stock deal valued at approximately $9 billion.

Coreweave stock fell about 4% on Monday while Core Scientific stock plummeted about 20%. Shares of both companies rallied at the end of June after the Wall Street Journal reported that talks were underway for an acquisition.

The deal strengthens CoreWeave’s position in the AI arms race by bringing critical infrastructure in-house.

CoreWeave CEO Michael Intrator said the move will eliminate $10 billion in future lease obligations and significantly enhance operating efficiency.

The transaction is expected to close in the fourth quarter of 2025, pending regulatory and shareholder approval.

Read more CNBC tech news

The deal expands CoreWeave’s access to power and real estate, giving it ownership of 1.3 gigawatts of gross capacity across Core Scientific’s U.S. data center footprint, with another gigawatt available for future growth.

Core Scientific has increasingly focused on high-performance compute workloads since emerging from bankruptcy and relisting on the Nasdaq in 2024.

Core Scientific shareholders will receive 0.1235 CoreWeave shares for each share they hold — implying a $20.40 per-share valuation and a 66% premium to Core Scientific’s closing stock price before deal talks were reported.

After closing, Core Scientific shareholders will own less than 10% of the combined company.

Continue Reading

Trending